Janssen Discontinues its 2018 License Agreement with Argenx for Cusatuzumab

 Janssen Discontinues its 2018 License Agreement with Argenx for Cusatuzumab

Shots:

  • The discontinuation is based on Janssen’s review of all available cusatuzumab data and in consideration of the evolving SOC for AML. Argenx regain its WW rights to cusatuzumab from Cilag
  • The P-Ib ELEVATE interim data will support the development of the anti-CD70 Ab in AML, whereas argenx plans to evaluate options to enable a path forward
  • Janssen will work with argenx to transition the cusatuzumab program back to argenx. Following the termination, argenx can elect that Janssen operationally support the treatment and follow-up of patients enrolled in ongoing cusatuzumab clinical studies

Click here to­ read full press release/ article | Ref: Janssen | Image: Janssen

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post